Evaluation of nav1.8 as a therapeutic target for pitt hopkins syndrome

HIGHLIGHTS

  • who: Keri Martinowich from the (UNIVERSITY) have published the paper: Evaluation of Nav1.8 as a therapeutic target for Pitt Hopkins Syndrome, in the Journal: (JOURNAL) of 12/Oct/2022
  • what: Currently there are no approved medications for the core symptoms of ASD or even subsets of ASD like PTHS.

SUMMARY

    Pitt Hopkins Syndrome (PTHS) is a rare neurodevelopmental disorder resulting from autosomal dominant mutations on chromosome 18 at the TCF4 (also known as ITF2, SEF2, E2-2, not T-cell factor 4 which is encoded by TCF7L2 gene) locus. The . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?